Current PSA level-Between 4 to 10 Posts on Medivizor
Navigation Menu

Current PSA level-Between 4 to 10 Posts on Medivizor

Comparing the survival outcomes of pembrolizumab with or without enzalutamide in men with previously untreated metastatic castration-resistant prostate cancer.

Comparing the survival outcomes of pembrolizumab with or without enzalutamide in men with previously untreated metastatic castration-resistant prostate cancer.

Posted by on Jun 12, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the survival and safety outcomes of pembrolizumab (Keytruda; PEM) plus enzalutamide (Xtandi; ENZ) combination versus pembrolizumab alone in patients with previously untreated metastatic castration-resistant prostate cancer (mCRPC). The data showed that PEM plus ENZ combination was associated with increased survival...

Read More

Evaluation of intermittent androgen deprivation therapy for locally advanced prostate cancer.

Evaluation of intermittent androgen deprivation therapy for locally advanced prostate cancer.

Posted by on May 19, 2021 in Prostate cancer | 0 comments

In a nutshell The study compared patient-reported outcomes (PRO) in patients receiving continuous androgen deprivation therapy (CADT) vs intermittent androgen deprivation therapy (IADT) for locally advanced prostate cancer (PCa). The study reported that PROs were significantly improved with IADT. Some background ADT is a hormonal therapy...

Read More

Do statins help the treatment of patients with prostate cancer using androgen-deprivation therapy?

Do statins help the treatment of patients with prostate cancer using androgen-deprivation therapy?

Posted by on Jan 24, 2021 in Prostate cancer | 0 comments

In a nutshell This study explored the outcomes of statin (cholesterol-lowering drugs) treatment in patients with prostate cancer (PCa) undergoing androgen deprivation therapy (ADT). The authors found that the combination of statins and ADT improved the outcomes of these patients and intermittent ADT (IADT) increased the time...

Read More

Does giving radiotherapy to metastatic sites and the prostate tumor improve the outcomes of patients with prostate cancer and few metastases?

Does giving radiotherapy to metastatic sites and the prostate tumor improve the outcomes of patients with prostate cancer and few metastases?

Posted by on Nov 25, 2020 in Prostate cancer | 0 comments

In a nutshell This study aims to evaluate if giving radiotherapy to both the areas the tumor has spread (metastases), along with the prostate tumor, will improve the survival of patients with prostate cancer (PC) and few metastases (oligometastatic disease). This study suggested that this treatment could benefit patients with PC and few...

Read More

Quality of life in patients with metastatic prostate cancer under cabazitaxel treatment

Quality of life in patients with metastatic prostate cancer under cabazitaxel treatment

Posted by on Oct 10, 2020 in Prostate cancer | 0 comments

In a nutshell The study compared the quality of life (QoL) of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel (Jevtana) compared to abiraterone (Zytiga) or enzalutamide (Xtandi). The authors found that cabazitaxel did not reduce QoL in such patients. Some background Patients with mCRPC...

Read More

Searching for patients with metastatic castration resistant prostate cancer to trial a biological treatment combination

Searching for patients with metastatic castration resistant prostate cancer to trial a biological treatment combination

Posted by on Aug 15, 2020 in Prostate cancer | 0 comments

In a nutshell This trial is examining the effectiveness of cabozantinib (Cabometyx) combined with atezolizumab (Tecentriq) for metastatic castration-resistant prostate cancer (mCRPC; cancer that is no longer responding to hormone therapy). The main outcomes to be measured are progression-free survival (PFS) and overall survival (OS) of...

Read More

Partial gland ablation versus prostate surgery in men with low- or intermediate-risk prostate cancer

Posted by on Nov 20, 2017 in Prostate cancer | 0 comments

In a nutshell The authors aimed to determine patient outcomes following partial gland ablation compared to robot-assisted radical prostate surgery in men with low- and intermediate- risk prostate cancer. The authors concluded that men with cancer confined to the prostate benefited from partial gland ablation, as it was more successful with fewer side...

Read More

The effect of anxiety and uncertainty on men under prostate cancer active surveillance

Posted by on Mar 4, 2017 in Prostate cancer | 0 comments

In a nutshell The authors aimed to determine how anxiety and uncertainty affects men with prostate cancer who are undergoing active surveillance.  The authors concluded that uncertainty and urinary complications promote anxiety in men on active surveillance for prostate cancer. They also recommend patient education and management of urinary...

Read More